EUROFINS SCIENT Total Long Term Liabilities 2018-2024 | ERFSF
EUROFINS SCIENT total long term liabilities from 2018 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
- EUROFINS SCIENT total long term liabilities for the quarter ending June 30, 2024 were $3.760B, a 4.08% increase year-over-year.
- EUROFINS SCIENT total long term liabilities for 2023 were $3.928B, a 7.75% increase from 2022.
- EUROFINS SCIENT total long term liabilities for 2022 were $3.646B, a 10.08% increase from 2021.
- EUROFINS SCIENT total long term liabilities for 2021 were $3.312B, a 8.33% decline from 2020.
| EUROFINS SCIENT Annual Total Long Term Liabilities (Millions of US $) |
|
|---|---|
| 2023 | $3,928 |
| 2022 | $3,646 |
| 2021 | $3,312 |
| 2020 | $3,613 |
| 2019 | $3,745 |
| 2018 | $3,582 |
| 2017 | $2,146 |
| 2016 | $0 |
| 2015 | $0 |
| EUROFINS SCIENT Quarterly Total Long Term Liabilities (Millions of US $) |
|
|---|---|
| 2023-06-30 | $3,760 |
| 2022-12-31 | $3,646 |
| 2021-12-31 | $3,312 |
| 2021-06-30 | $3,365 |
| 2020-12-31 | $3,613 |
| 2020-06-30 | $3,516 |
| 2019-12-31 | $3,745 |
| 2019-06-30 | $3,305 |
| 2018-12-31 | $3,582 |
| 2018-06-30 | $2,288 |
| 2017-12-31 | $2,146 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $12.189B | $7.522B |
| Eurofins Scientific SE provides testing services. The company provides food and feed testing, bioanalytical, biopharma, pharma discovery, pharma early development, pharma central laboratory, biopharma product testing, genomic, agroscience, consumer product testing, forensic, environment testing and REACH services. It operates primarily in Benelux, France, Germany, North America, Nordic countries, the United Kingdom, Ireland and internationally. Eurofins Scientific SE is headquartered in Luxembourg. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $136.013B | 25.51 |
| Elevance Health (ELV) | United States | $93.532B | 12.07 |
| CVS Health (CVS) | United States | $83.782B | 10.41 |
| Cencora (COR) | United States | $56.393B | 20.47 |
| Natera (NTRA) | United States | $21.021B | 0.00 |
| DiDi Global (DIDIY) | China | $20.473B | 31.07 |
| BioMerieux (BMXMF) | France | $15.263B | 0.00 |
| CochLear (CHEOY) | Australia | $11.336B | 0.00 |
| Solventum (SOLV) | United States | $11.327B | 10.56 |
| ICON (ICLR) | Ireland | $10.910B | 10.14 |
| Revvity (RVTY) | United States | $10.864B | 18.34 |
| Doximity (DOCS) | United States | $10.660B | 55.44 |
| Viatris (VTRS) | United States | $10.056B | 3.20 |
| Medpace Holdings (MEDP) | United States | $8.300B | 22.04 |
| Avantor (AVTR) | United States | $8.164B | 11.86 |
| Sonic Healthcare (SKHHY) | Australia | $8.076B | 0.00 |
| HealthEquity (HQY) | United States | $7.797B | 38.36 |
| Charles River Laboratories (CRL) | United States | $5.668B | 11.18 |
| Amplifon S.p.A (AMFPF) | Italy | $4.736B | 25.00 |
| Bausch + Lomb (BLCO) | Canada | $3.852B | 22.71 |
| BrightSpring Health Services (BTSG) | United States | $3.804B | 35.21 |
| Sotera Health (SHC) | United States | $3.648B | 20.73 |
| Alignment Healthcare (ALHC) | United States | $3.110B | 0.00 |
| Surgery Partners (SGRY) | United States | $2.950B | 33.84 |
| Concentras Parent (CON) | United States | $2.781B | 14.47 |
| Organon (OGN) | United States | $2.373B | 2.52 |
| Premier (PINC) | United States | $2.095B | 14.34 |
| Progyny (PGNY) | United States | $2.001B | 44.08 |
| Ardent Health Partners (ARDT) | United States | $1.857B | 7.93 |
| Agilon Health (AGL) | United States | $1.842B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.776B | 69.53 |
| GoodRx Holdings (GDRX) | United States | $1.634B | 35.50 |
| PACS (PACS) | United States | $1.503B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.243B | 9.46 |
| Teladoc Health (TDOC) | United States | $1.189B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.039B | 0.00 |
| Establishment Labs Holdings (ESTA) | $0.952B | 0.00 | |
| CareDx (CDNA) | United States | $0.790B | 12.33 |
| AMN Healthcare Services Inc (AMN) | United States | $0.748B | 5.92 |
| Nutex Health (NUTX) | United States | $0.735B | 14.39 |
| Embecta (EMBC) | United States | $0.710B | 4.86 |
| QDM (QDMI) | Hong Kong, SAR China | $0.671B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.518B | 13.73 |
| Sonida Senior Living (SNDA) | United States | $0.440B | 0.00 |
| Enhabit (EHAB) | United States | $0.407B | 38.29 |
| InnovAge Holding (INNV) | United States | $0.385B | 0.00 |
| LifeMD (LFMD) | United States | $0.341B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.338B | 0.00 |
| SBC Medicals (SBC) | United States | $0.323B | 0.00 |
| DocGo (DCGO) | United States | $0.239B | 9.75 |
| Oncology Institute (TOI) | United States | $0.197B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.177B | 0.00 |
| Beauty Health (SKIN) | United States | $0.132B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.095B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.089B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.087B | 0.00 |
| So-Young (SY) | China | $0.087B | 0.00 |
| OncoCyte (OCX) | United States | $0.083B | 0.00 |
| Biodesix (BDSX) | United States | $0.066B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.059B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.031B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.027B | 0.00 |
| ModivCare (MODV) | United States | $0.020B | 7.10 |
| KindlyMD (KDLY) | United States | $0.018B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.012B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.004B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |